Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov;68(2):172-7.
doi: 10.1016/j.critrevonc.2008.06.006. Epub 2008 Aug 15.

Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study

Gijsberta J van Londen  1 , Matthew E Levy, Subashan Perera, Joel B Nelson, Susan L Greenspan
Affiliations
Clinical Trial

Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study

Gijsberta J van Londen et al. Crit Rev Oncol Hematol. 2008 Nov.

Abstract

Background: Little is known about the long-term impact of androgen deprivation therapy (ADT) on body composition in men with prostate cancer. We compared body composition parameters in men with non-metastatic prostate cancer on or not on therapy with healthy, age-matched controls at baseline and monitored changes over a 2-year period.

Methods: We measured body fat mass and lean body mass in 81 men with prostate cancer on no ADT, 43 men on acute ADT (less than 6 months), 67 men on chronic ADT (more than 6 months) and 53 age-matched healthy controls. Measurements were performed every 6 months for 2 years.

Results: Men with prostate cancer on acute ADT (mean 3 months) had significant gains in body fat mass [1499.56+/-322.28g (mean+/-S.E.) after 12 months, 2167.15+/-676.45g after 24 months, p<0.01 for both] and losses in lean body mass (929.74+/-296.36g after 12 months, 1785.81+/-501.31g after 24 months, p<0.01 for both) over 2 years. Men on chronic ADT (mean 31 months) had smaller but still significant body composition changes over 24 months. Changes in body composition in men on no ADT were small and healthy controls had no significant changes.

Conclusions: Men with prostate cancer on ADT have significant gains in body fat mass and losses lean body mass over 2 years. These changes are most pronounced with initiation of ADT.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes from baseline in (a) total body fat mass (g) and (b) percent body fat over 24 months. Results are shown as mean ± S.E. (a) p = 0.0024 across all groups at 24 months. (b) p < 0.0001 across all groups at 24 months. Abbreviations: ADT, androgen deprivation therapy.
Fig. 2
Fig. 2
Changes from baseline in (a) total lean body mass (g) and (b) percent lean mass over 24 months. Results are shown as mean ± S.E. (a) p = 0.0630 across all groups at 24 months. (b) p < 0.0001 across all groups at 24 months. Abbreviations: ADT, androgen deprivation therapy.
See this image and copyright information in PMC

References

    1. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60:201–15. - PubMed
    1. Basaria S, Lieb J, 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779–86. - PubMed
    1. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7. [discussion: 2367] - PubMed
    1. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005;8:207–12. - PubMed
    1. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136–44. - PubMed

Publication types

Substances